DK3269735T3 - Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf - Google Patents
Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf Download PDFInfo
- Publication number
- DK3269735T3 DK3269735T3 DK16764142.2T DK16764142T DK3269735T3 DK 3269735 T3 DK3269735 T3 DK 3269735T3 DK 16764142 T DK16764142 T DK 16764142T DK 3269735 T3 DK3269735 T3 DK 3269735T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigin
- binding fragment
- antibody against
- medical use
- against sclerostin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510112924 | 2015-03-13 | ||
| PCT/CN2016/073857 WO2016145961A1 (zh) | 2015-03-13 | 2016-02-16 | 抗硬骨素抗体、其抗原结合片段及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3269735T3 true DK3269735T3 (da) | 2020-12-14 |
Family
ID=56919707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16764142.2T DK3269735T3 (da) | 2015-03-13 | 2016-02-16 | Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10449250B2 (da) |
| EP (2) | EP3269735B1 (da) |
| JP (1) | JP6755513B2 (da) |
| KR (1) | KR102584953B1 (da) |
| CN (2) | CN106661104B (da) |
| AU (1) | AU2016232897B2 (da) |
| BR (1) | BR112017019075A2 (da) |
| CA (1) | CA2978976C (da) |
| DK (1) | DK3269735T3 (da) |
| ES (1) | ES2835923T3 (da) |
| HR (1) | HRP20201862T1 (da) |
| HU (1) | HUE052528T2 (da) |
| LT (1) | LT3269735T (da) |
| MX (1) | MX2017011480A (da) |
| PT (1) | PT3269735T (da) |
| RS (1) | RS61158B1 (da) |
| RU (1) | RU2716101C2 (da) |
| SI (1) | SI3269735T1 (da) |
| TW (2) | TWI790617B (da) |
| WO (1) | WO2016145961A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127219C2 (uk) * | 2017-07-27 | 2023-06-14 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, що містить анти-sost антитіло, та її застосування |
| CN108101984B (zh) * | 2017-12-18 | 2019-10-15 | 中国人民解放军总医院 | 骨硬化蛋白单链抗体的制备方法和用途 |
| JP7120531B2 (ja) * | 2018-02-12 | 2022-08-17 | アプタキュア セラピューティクス リミテッド | スクレロスチンに対するアプタマー及びその使用 |
| CN113913463B (zh) * | 2021-09-19 | 2023-08-18 | 郭保生 | 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用 |
| TW202330032A (zh) * | 2021-11-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗ｓｏｓｔ抗體醫藥組成物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO345763B1 (no) * | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
| PT2119452T (pt) * | 2006-12-26 | 2020-05-08 | Ct Inmunologia Molecular | Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide |
| US7744874B2 (en) * | 2007-03-20 | 2010-06-29 | Eli Lilly And Company | Anti-sclerostin antibodies |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| EP2227256A1 (en) * | 2007-12-14 | 2010-09-15 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CA2853258A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against sclerostin |
| BR112014016108A2 (pt) * | 2011-12-28 | 2018-09-11 | Amgen Inc | método de tratamento de perda óssea alvelar |
| AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
-
2016
- 2016-02-16 RU RU2017132924A patent/RU2716101C2/ru active
- 2016-02-16 BR BR112017019075-3A patent/BR112017019075A2/pt active Search and Examination
- 2016-02-16 CA CA2978976A patent/CA2978976C/en active Active
- 2016-02-16 EP EP16764142.2A patent/EP3269735B1/en active Active
- 2016-02-16 RS RS20201482A patent/RS61158B1/sr unknown
- 2016-02-16 US US15/556,488 patent/US10449250B2/en active Active
- 2016-02-16 LT LTEP16764142.2T patent/LT3269735T/lt unknown
- 2016-02-16 JP JP2017546934A patent/JP6755513B2/ja active Active
- 2016-02-16 ES ES16764142T patent/ES2835923T3/es active Active
- 2016-02-16 KR KR1020177027816A patent/KR102584953B1/ko active IP Right Grant
- 2016-02-16 DK DK16764142.2T patent/DK3269735T3/da active
- 2016-02-16 HU HUE16764142A patent/HUE052528T2/hu unknown
- 2016-02-16 AU AU2016232897A patent/AU2016232897B2/en active Active
- 2016-02-16 CN CN201680001851.5A patent/CN106661104B/zh active Active
- 2016-02-16 PT PT167641422T patent/PT3269735T/pt unknown
- 2016-02-16 WO PCT/CN2016/073857 patent/WO2016145961A1/zh active Application Filing
- 2016-02-16 MX MX2017011480A patent/MX2017011480A/es unknown
- 2016-02-16 CN CN201910168894.8A patent/CN111196849B/zh active Active
- 2016-02-16 EP EP20197476.3A patent/EP3782641A1/en active Pending
- 2016-02-16 SI SI201630983T patent/SI3269735T1/sl unknown
- 2016-03-02 TW TW110117739A patent/TWI790617B/zh active
- 2016-03-02 TW TW105106269A patent/TWI730954B/zh active
-
2020
- 2020-11-23 HR HRP20201862TT patent/HRP20201862T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3476399T3 (da) | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf | |
| DK3303396T3 (da) | Antistoffer mod ox40 og anvendelser deraf | |
| DK3347379T3 (da) | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf | |
| DK3271389T3 (da) | Neutraliserende antistoffer mod gp120 og anvendelse deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3337549T3 (da) | Kateteranordninger med ventiler og tilhørende fremgangsmåder. | |
| DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
| DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3182999T3 (da) | Anti-lag3-antistoffer og antigenbindingsfragmenter | |
| DK3107938T3 (da) | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf | |
| DK3081576T3 (da) | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf | |
| DK3168283T3 (da) | Hydrokrakning-katalysator, fremstillingsfremgangsmåde og anvendelse deraf | |
| DK3265575T3 (da) | Cd20-bindende molekyler og anvendelser deraf | |
| DK3360878T3 (da) | Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf | |
| DK3319428T3 (da) | Herbicid sammensætning omfattende cinmethylin og imazamox | |
| DK3142750T3 (da) | Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf | |
| BR112016018521A2 (pt) | composição, e, kit. | |
| DK3354661T3 (da) | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf | |
| DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| DK3283524T3 (da) | BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3 | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf |